Free Trial
→ Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX (From InvestorPlace) (Ad)tc pixel
NASDAQ:ADIL

Adial Pharmaceuticals 5/13/2026 Earnings Report

Adial Pharmaceuticals logo
$1.60 0.00 (0.00%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$1.60 -0.01 (-0.31%)
As of 05/5/2026 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Adial Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$2.73
Beat/Miss
N/A
One Year Ago EPS
N/A

Adial Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adial Pharmaceuticals Announcement Details

Quarter
Date
5/13/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Adial Pharmaceuticals Earnings Headlines

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283847/26135/en/adial-pharmaceuticals-advances-ip-portfolio-with-new-u-s-utility-patent-application-positioning-for-potential-market-exclusivity-through-2045.html
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
April 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/adial-pharmaceuticals-submits-application-fda-124700262.html
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
 |  Weiss Ratings (Ad)
Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3281641/26135/en/adial-pharmaceuticals-submits-application-to-fda-commissioner-s-national-priority-voucher-cnpv-pilot-program-for-ad04-clinical-development-program.html
Adial Pharmaceuticals Achieves Successful Demonstration Batch Production for AD04, Advancing Phase 3 Clinical Development Plans
April 22, 2026  |  quiverquant.comQ
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3279087/26135/en/adial-pharmaceuticals-successfully-completes-manufacturing-of-demonstration-batch-production-enabling-clinical-and-registration-production-for-ad04-planned-phase-3-trial.html
See More Adial Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email.

About Adial Pharmaceuticals

Adial Pharmaceuticals (NASDAQ:ADIL), incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence. This extended-release formulation aims to improve compliance and reduce relapse rates by maintaining therapeutic drug levels without the need for daily dosing. In addition to AD04, Adial is evaluating next-generation implant platforms and potential adjunctive therapies for substance use disorders, seeking to broaden its pipeline through strategic collaborations and in-house research efforts.

Adial conducts clinical research primarily in North America, with previous trials extending to select international sites to gather comprehensive safety and efficacy data supporting future regulatory filings. The company operates through partnerships with academic institutions, contract research organizations and specialized clinical investigators to advance its development programs. Led by an executive team with extensive experience in pharmaceutical development, regulatory affairs and commercialization, Adial Pharmaceuticals continues to focus on addressing global challenges in addiction medicine and preparing for regulatory submissions that could pave the way for market entry.

View Adial Pharmaceuticals Profile
Earnings Tools